US2006276531A1PendingUtilityA1

Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia

Assignee: UNIV PITTSBURGHPriority: Mar 30, 2001Filed: Aug 14, 2006Published: Dec 7, 2006

Est. expiryMar 30, 2021(expired)· nominal 20-yr term from priority

Inventors:Tsuyoshi Yamagata Kaoru Atsuki Tetsuji Ohno Shiro Shirakura Akira Karasawa William De Groat Naoki Yoshimura Adrian Sculptoreanu

A61K 31/38A61P 13/10A61P 13/08A61K 31/44A61P 13/00A61K 31/55

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K + channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K + channel opening activity as an index.

Claims

exact text as granted — not AI-modified

1 . A pharmaceutical composition comprising, as an active ingredient, a compound having a slowly-inactivating A-type K +  channel opening activity or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.  
   
   
       2 . The pharmaceutical composition according to  claim 1 , wherein the compound having a slowly-inactivating A-type K +  channel opening activity is N-(5,5-dioxido-10-oxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide.  
   
   
       3 . A method for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claims  1  or  2 .  
   
   
       4 . A method for preparing a pharmaceutical composition for treating bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising selecting a slowly-inactivating A-type K +  channel opening activity, or a pharmaceutically acceptable salt thereof, and admixing said compound or salt with a pharmaceutically acceptable carrier.  
   
   
       5 . (canceled)  
   
   
       6 . The method according to  claim 4 , wherein said compound having a slowly-inactivating A-type K +  channel opening activity is N-(5,5-dioxido-10-oxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide.

Join the waitlist — get patent alerts

Track US2006276531A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.